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On the basis of this definition, approximately 30% to 45% of the treated hypertension population in the United States was found to be "controlled" using data from the 1988 to 1991 National Health and Nutrition Examination Survey (NHANES). 2 According to estimates from the latest NHANES survey (1999 -2000) BP control in the United States has improved; however, 47% of treated hypertensive patients are still not at BP goal. 3 In an effort to reinforce the significance of BP control in special populations, a number of guidelines committees have recommended lower treatment goals of 130/85 or 130/80 mm Hg in patients with diabetes or chronic kidney disease. 1, 4, 5 Blood pressure management has not been effective despite recommendations from treatment guidelines and the availability of care. Hyman and Pavlik 6 demonstrated that most cases of uncontrolled hypertension occur in patients more than 65 years of age who have good access to health care and relatively frequent contact with physicians. Of patients more than age 65 years with treated but uncontrolled hypertension, 87.6% had a systolic BP of more than 140 mm Hg and 1.3% had a diastolic BP of more than 90 mm Hg. In comparison, 66.1% of patients aged 45 to 64 years with treated but uncontrolled hypertension had a systolic BP of more than 140 mm Hg and 2.8% had a diastolic BP of more than 90 mm Hg. The prevalence of uncontrolled systolic BP is 47% to 77% among hypertensive patients with angina, obesity, and diabetes, as well as African American and elderly populations. These epidemiologic findings indicate that current hypertension treatment strategies are suboptimal, particularly in treating systolic BP.
Clinicians increasingly suggest that hypertension can be better managed by switching strategies from monotherapy to multiple medications. Cushman 7 advocated that a large proportion of patients with systolic hypertension would require at least two or three antihypertensive drugs (AHDs) to achieve the systolic and diastolic BP goals recommended in the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC) 6 and other guidelines. Bakris 8 provided a similar recommendation, particularly in reference to patients with diabetes, citing that only half of all hypertensive patients respond to monotherapy and that hypertension is a multifactorial disease with multiple pathways contributing to increased BP. Therefore, the use of multiple AHDs may provide better BP control through complementary interruption to these pathways.
Landmark clinical outcomes trials have provided consistent evidence to support the need for multiple therapies to obtain adequate BP control in complicated hypertension. A review of trials including United Kingdom Prospective Diabetes Study (UKPDS) and Hypertension Optimal Treatment (HOT) study indicated that 2.8 to 4.2 different agents were required to achieve the desired BP. 8 More recently, in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial and the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT), at least 66% and 63% of subjects, respectively, required two or more AHDs to reach goal. 4, 9, 10 Therefore, despite a plethora of research into the effectiveness of various therapies in complicated hypertension, the information remains unclear as to which class, agent, and treatment regimen is the most appropriate for different types of patients as initial therapy, or in combination. Such limitation prompts the need to assess the clinical effectiveness of commonly prescribed agents in any of the major antihypertensive classes that are frequently used in different treatment regimens.
The long-acting dihydropyridine calcium channel blockers have several properties that make them attractive for the treatment of hypertension. Amlodipine besylate (Norvasc; Pfizer Inc., New York, NY), the most commonly prescribed drug in this class, has demonstrated clinical efficacy for the reduction of BP. Although the clinical features of this medication are well documented in a clinical trial environment, the effectiveness in typical physician office practice has not been well elucidated. In addition, the effectiveness of amlodipine as add-on therapy to other AHDs in a clinical practice setting has not been established. Therefore, the objectives of this study are to measure BP reduction and BP goal attainment (defined as Ͻ140/90 mm Hg, or Ͻ130/80 mm Hg in patients with diabetes, according to the JNC 6, JNC 7, and American Diabetes Association [ADA] guidelines) in patients initiated on amlodipine in a naturalistic physician office environment, and to describe the effectiveness of amlodipine as first-, second-, and third-line therapy for patients with uncontrolled hypertension. Secondary objectives are to examine the effectiveness of amlodipine in diabetic and elderly (aged 65 years or older) populations and as add-on therapy to specific antihypertensive regimens.
Methods

Data Source
This was a retrospective database analysis using data extracted from the GE Medical Quality Improvement Consortium Electronic Medical Records (EMR) database. This EMR database captures longitudinal clinical information directly from the clinical encounter, including demographics, diagnoses, medications, cardiac risk factors, tests, test results, procedures, functional status, and other data elements for approximately 400,000 patients receiving ambulatory care treatment at more than 500 physicians' offices across the United States. These physicians are located in practices in the states of Oregon, Arizona, Texas, Iowa, Virginia, New Hampshire, and Maine. All practices have been using the EMR for at least 1 year at the time the study was initiated.
Patient Selection
Patients Ն20 years of age who were initiated on amlodipine from 1998 to 2001 were identified for the study. Each patient was required to have two valid BP readings, a preindex reading being the last measurement within 180 days before the initiation of amlodipine and a postindex measurement, defined as the last measurement within 30 to 360 days after the initiation of amlodipine. Hypertension was classified according to the most recent JNC 7 guidelines; however, BP goal attainment included the recommendations from JNC 6 and ADA to correspond with the 1998 to 2001 study period. The former BP reading was required to be greater than 140/90 mm Hg for nondiabetic patients and greater than 130/80 mm Hg for diabetic patients. The latter BP reading must have occurred before the earliest of the following events: 1) discontinuation of amlodipine, 2) initiation of any other AHD, or 3) 360 days after initiation of amlodipine. Therefore, patients who were initiated on other AHDs on the same day or within the first 30 days of amlodipine were excluded, as were patients who were discontinued from amlodipine less than 30 days after its initiation. Patients with a documented diagnosis of congestive heart failure (CHF) or with prior use of any calcium channel blocker were excluded from the analysis.
Data Collection
Patient age, sex, and weight at baseline were collected to describe patient demographics. Diagnoses for diabetes and cardiovascular events recorded during the study period were collected for comparison of severity across patient groups. Charlson's comorbidity index was calculated from ICD-9 codes using the coding algorithm described by Romano et al. 11, 12 This index creates a single score based on the sum of a weighted ranking of diagnoses and has been used to compare the health status of different patient groups.
Prior antihypertensive therapy was defined as the use of any AHDs before the start of amlodipine, which were not discontinued on or before the start of amlodipine therapy. Prior AHDs were classified into the following groups using Generic Product Indicator (GPI) codes: angiotensinconverting enzyme (ACE) inhibitors/angiotensin receptor blockers, ␤-blockers, diuretics, other (␣-blockers, vasodilators, methyldopa). Patients using fixed-dose combination products were classified as receiving AHDs in each of the classes. Patients were classified in one of the following four groups based on the number of AHD classes they were receiving at the start of amlodipine: no other AHD (amlodipine monotherapy), amlodipine ϩ 1 AHD, amlodipine ϩ 2 AHDs, and amlodipine ϩ Ն3 AHDs.
Baseline BP was defined as the final BP reading on or before the date of amlodipine initiation and within 180 days prior. Final BP was defined as the last valid BP reading after 30 days and before the earliest of a regimen change, amlodipine discontinuation, or 360 days. Blood pressure goal attainment was calculated as the percentage of patients with a final BP reading of Ͻ140/90 mm Hg, among those with a baseline BP reading of Ͼ140/90 mm Hg. In a subanalysis of diabetic patients, percentage reaching goal was calculated as both the percentage with a final BP reading Ͻ140/90 mm Hg and the percentage with a final BP reading Ͻ130/80 mm Hg.
Statistical Analysis
All categorical variables were presented as the sum and percentage of patients. Continuous variables were presented as mean and standard deviation. Baseline characteristics were compared using a 2 test for categorical variables and ANOVA for continuous variables.
Adjusted mean change in systolic BP for each prior medication group was calculated using ordinary least squares regression with covariates of age, sex, baseline systolic BP, number of prior AHDs, Charlson's comorbidity index, and time from pre-to post-BP reading. Adjusted mean systolic BP reduction was also calculated for diabetic patients and patients Ͼ65 years of age.
All analyses were conducted using SAS version 8. 
Results
Baseline Characteristics
Of 171,123 patients with documented hypertension in the database, 10,481 received amlodipine. Of these patients, 4281 had valid BP readings in the pre-and postperiods, and 3239 of these patients were hypertensive on their preindex BP reading. After applying date restrictions, age restrictions, and excluding patients with CHF and patients with concurrently started AHDs, there were 1175 patients remaining for inclusion in the study (Fig. 1) .
Of the 1175 patients in the study sample, 37% were in the monotherapy group (n ϭ 421), 27% were in the 1 prior AHD group (n ϭ 321), 23% were in the 2 prior AHDs group (n ϭ 276), and 13% were in the Ն3 prior AHDs group (n ϭ 157). Mean age overall was 65.9 years (SD: 14.7), with the lowest mean age in the monotherapy group (mean: 64.1 years, SD: 14.7) and the greatest in the Ն3 prior AHDs group (mean: 68.1 years, SD: 12.8). Approximately 60% of the patients were women. Weight differed significantly across the groups, with the greatest mean weight in patients with Ն3 prior AHDs (mean: 193 lbs, SD: 52.1 lbs) and the lowest weight in the 1 prior AHD group (mean: 180.4 lbs, SD: 47.9 lbs). The proportion of patients with diabetes and prior myocardial infarction also increased as the number of prior AHDs increased (Table  1) . There was no significant difference in the dose of amlodipine administered in the four treatment groups; the mean final dose in each of the cohorts (ie, 0, 1, 2, Ն3 prior AHDs) was 6.5, 5.8, 5.9, and 6.1 mg, respectively, and the median dose in each group was 5 mg.
Mean systolic and diastolic BP before amlodipine initiation were 159.5 mm Hg (SD: 19.5 mm Hg) and 88.3 mm Hg (SD: 13.1 mm Hg), respectively. Previous systolic BP was generally higher as the number of prior AHDs increased ( Table 2) . The majority of patients in the monotherapy group were in JNC 6/7 stage 1 at initiation of therapy (n ϭ 212, 50.4%). The proportion of patients in stage 1 decreased as the number of prior AHDs increased, from 42.7% of patients in the 1 prior AHD group to 31.8% in patients who used Ն3 prior AHDs.
BP Outcomes
Patients received an average of 2.8 BP readings in the 6 months before the initiation of amlodipine, and 4.7 BP readings in the next 12 months. Patients in the monotherapy cohort received the fewest BP readings (pre: 1.8; post: 4.6), whereas patients in the Ն3 prior AHDs group received the most (pre: 4.0; post: 4.9). The mean time from initiation of amlodipine to the nearest prior BP reading was 5.7 days (median: 0 days), and the mean time to the post-BP reading was 229 days (median: 252 days; Table  2 ).
Systolic and diastolic BP decreased significantly in each group after therapy. Mean change in systolic BP was Ϫ13.5, Ϫ17.8, Ϫ19.4, and Ϫ18.0 mm Hg in the 0, 1, 2, and Ն3 prior AHD groups. Mean change in diastolic BP was Ϫ7.4, Ϫ9.1, Ϫ9.0, and Ϫ7.7 mm Hg in the 0, 1, 2, DBP ϭ diastolic blood pressure; SBP ϭ systolic blood pressure; other abbreviations as in Table 1 .
and Ն3 prior AHD groups. More than 35% of patients who were not at BP goal at baseline achieved their BP goal in the year after treatment, with BP goal attainment in 39%, 45%, 41%, and 45% in the 0, 1, 2, and Ն3 prior AHD groups, respectively (Table 3) . Adjusting for differences in baseline characteristics, changes in systolic and diastolic BP were consistent across all the groups, with adjusted mean SBP changes of Ϫ16.1, Ϫ17.6, Ϫ16.7, and Ϫ15.7 mm Hg in the 0, 1, 2, and Ն3 prior AHD groups, respectively (Table 4) . Among patients with diabetes, there was a consistent and significant reduction in systolic BP across treatment groups, with an adjusted mean change of Ϫ13.4, Ϫ14.2, Ϫ15.1, and Ϫ15.6 mm Hg in the 0, 1, 2, and Ն3 prior AHD groups. More than 34% of patients with diabetes in each group reached the BP goal of Ͻ140/90 mm Hg; however, only ϳ15% were able to meet the more stringent diabetic BP goal of Ͻ130/80 mm Hg. Patients aged Ն65 years had an adjusted mean change of Ϫ13.4, Ϫ14.2, Ϫ15.1, and Ϫ15.6 mm Hg in systolic BP in the 0, 1, 2, and Ն3 prior AHD groups. Blood pressure goal attainment was more than 40% across all amlodipine groups ( Table 5) .
As shown in Table 6 , amlodipine was effective in lowering both systolic and diastolic BP regardless of the type of AHDs it was combined with. For example, for patients prescribed amlodipine in combination with an ACE inhibitor or angiotensin II receptor blocker (ARB), the adjusted mean reduction in systolic BP was Ϫ14.9 mm Hg (95% confidence interval [CI]: Ϫ18.3, Ϫ11.5) and diastolic BP was Ϫ7.7 mm Hg (95% CI: Ϫ9.5, Ϫ5.8).
Discussion
Blood pressure goal attainment was defined by the guidelines from JNC 6 and ADA in accordance with the period of patient analysis between 1998 and 2001. These guidelines have subsequently been incorporated into the latest JNC 7 recommendations, which underscore the importance of aggressive and appropriate treatment of hypertension to established targets for patients of all ages. The JNC 7 guidelines recognize that every 20/10 mm Hg decrease in BP is associated with a 50% decrease in cardiovascular disease. They further acknowledge that treatment to the established goals of 140/90 mm Hg (or 130/80 mm Hg in patients with diabetes or renal insufficiency) can often be accomplished only by use of multiple medications. In acknowledging that cardiovascular risk continuously increases once BP is more than 115/75 mm Hg, simply using the 140/90 mm Hg (or 130/80 mm Hg) goal as an absolute lower limit for treatment is unlikely to optimize cardiovascular risk management. Instead, based on the extrapolation of current epidemiologic data treating patients until they are comfortably at or below their target is likely to be the best strategy for cardiovascular risk minimization. Abbreviations as in Tables 1 and 2 . * Patients not at JNC 6, JNC 7, and ADA goal at baseline. Abbreviations as in Tables 1 and 2 .
This study illustrates that long-acting dihydropyridine calcium channel blockers, such as amlodipine, can be effectively added to patients' antihypertensive regimen and result in a substantial incremental drop in BP, regardless of the number of AHDs with which a patient is already being treated. Of note, only about 40% to 45% of patients treated with two and three AHDs in this study achieved their BP goal, and the addition of amlodipine resulted in approximately 16 mm Hg of BP reduction in these patients. Although the level to which BP must be lowered to achieve optimal cardiovascular benefit has not been determined, 14 the mean reduction of 16 mm Hg can be regarded as a clinically meaningful difference. The addition of amlodipine resulted in a significant decrease in both systolic and diastolic BP in all groups, and had a nearly identical effect in the elderly patients-a group of patients who are at particular risk for the devastating effects of hypertension such as stroke and diastolic heart failure.
Many patients will have specific indications for particular classes of medications, such as ␤-blockade, inhibition of the renin-angiotensin system with ACE inhibitors or ARBs, or diuretics; but many of the patients continue to be hypertensive despite aggressive treatment with multiple agents. Numerous trials, including the ALLHAT trial, have shown amlodipine to be safe and effective in the treatment of hypertension, and extremely well tolerated from a side-effect standpoint. 10 This data analysis shows that, regardless of the number of AHDs that a patient is taking (from 0 to 3), the addition of amlodipine yields a substantial improvement in both systolic and diastolic BP. In addition, data analysis reveals a consistent trend in BP reduction regardless of the specific AHD class that is combined with amlodipine. Although the results suggest that adding amlodipine to the diuretic group achieves the greatest reduction, the small sample sizes meant we were unable to demonstrate a significant difference. Furthermore, the consistent BP results observed in both the diabetes group and cohorts previously treated with ACE inhibitors or ARBs (both frequently used in diabetes patients for their renal benefit) confirms the effectiveness of amlodipine in these patients who require aggressive BP management. Upcoming trials, such as the Amlodipine Diabetic Hypertension Efficacy REsponse (ADHERE) trial are expected to provide further insight into the combined efficacy of amlodipine and ACE inhibitors/ARBs in the diabetes cohort.
Observational analyses, such as the analysis reported here, are not intended to replace randomized controlled studies, as the former are more susceptible to biases, nor should any causality be inferred from the results of such an analysis. 15 A limitation of this analysis, as with any retrospective database analysis, is the potential for systematic selection of treatment in a population based on unobserved or unrecorded characteristics of the population that are not available in the database. The sample in this analysis consists of patients treated in a general practice setting, by 
(41%)
Abbreviations as in Tables 1 and 2. * Patients not at JNC 6, JNC 7, and ADA goal at baseline.
physicians using an EMR system to track the outcomes of their patients. Therefore, the results may not be "generalizable" to populations treated by other physicians. As with chart review, this study is limited by the accuracy of the data within the patient's chart. This and other such studies must rely on careful study design, replication, and multivariate analytical techniques to control for biases that may result from potential confounding variables. Another limitation of this evaluation is the inability to account for patient adherence and persistence with medications, which may impact outcomes attributed to those medications. Unfortunately, the discontinuation rate among patients receiving amlodipine, or other AHDs, was not well documented in patient records, presumably because patients failed to report such an event to their physicians. As a consequence, it was not possible to determine the number of patients who discontinued medication due to adverse events. Although reduction in mean BP may be a consequence of regression to the mean, this is unlikely to explain the consistency and magnitude of the observed effect in this study. Prior research has indicated that the placebo effect in clinical trials is usually in the order of 7.2/4.7 mm Hg difference in systolic and diastolic BP, respectively. 16 All of the cohorts in this study demonstrated a substantially greater BP lowering effect that was Ն14/6 mm Hg. Furthermore, the consistent decrease observed across all of the cohorts (especially those where prior therapy was unsuccessful at lowering BP) can be explained by the fact that the BP lowering effect of dihydropyridine calcium channel blockers, such as amlodipine, has been shown to be dependent on baseline BP, 17 which in this analysis was similar across cohorts. However, future research is needed to provide additional insights into characterizing the incremental BP lowering effect of antihypertensive agents when used in combination.
Nevertheless, the ability to characterize the impact of treatment under "actual practice" conditions in populations not often included in clinical trials (ie, the elderly or those with multiple chronic conditions) provides a great benefit. 18 Furthermore, despite the limitations of observational studies, emerging evidence suggests that findings of observational studies for pharmacologic interventions are often similar to those of large, randomized, controlled trials. 19, 20 The JNC 7 has reinforced the importance of treatment of both systolic and diastolic BP to goal in patients of all ages. This analysis shows that the use of dihydropyridine calcium channel blocking agents, such as amlodipine, can be effective in assisting patients to achieve these goals both as adjunct or primary therapy. ACEI ϭ angiotensin-converting enzyme inhibitor; ARB ϭ angiotensin II receptor blocker; CI ϭ confidence interval; other abbreviations as in Tables 1 and 2. 
